Oncoinvent ASA, a clinical stage radiopharmaceutical company advancing alpha emitter therapy across a variety of peritoneal metastases, announced the appointment of Oystein Soug as Chief Executive Officer (CEO), effective September 1, 2024. Mr. Soug brings over a decade of experience in research and development and product launch, including radiopharmaceutical products, having held leadership roles across several biotechnology companies. He succeeds CEO Anders Månsson, who has resigned for personal reasons.
“As Oncoinvent enters a critical growth phase with its ongoing Phase 2 study of Radspherin® in patients with peritoneal carcinomatosis from ovarian cancer, Oystein’s deep leadership experience within radiopharmaceutical product development will be invaluable. I look forward to working with him and the leadership team to develop novel products that use innovative radiopharmaceutical technology to deliver precise, alpha-emitting particles for the treatment of solid cancers,” said Gillies O’Bryan-Tear, MD, Chairperson of the Board of Oncoinvent. “On behalf of the Board, we thank Anders for his many contributions, and wish him the best in the future.”
Also Read: Pillar Biosciences Unveils oncoReveal Nexus for Targeted Therapy
“I am thrilled to join the talented team at Oncoinvent and build upon the company’s many accomplishments and impressive capabilities,” said Oystein Soug. “With the ongoing Phase 2 study of Radspherin® in ovarian cancer, supported by highly encouraging data from earlier clinical studies across both ovarian and colorectal cancer patients, we are poised to reach meaningful milestones over the coming year. It is a privilege to lead a company with tremendous potential to bring novel alpha-emitters into clinical use, which can be used for the treatment of a variety of cancer indications.”
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CEO of Targovax, an Oslo-listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
SOURCE: Businesswire